Cemiplimab is a fully human and hinge-stabilized IgG4 (S228P) kappa monoclonal antibody that tightly binds to PD-1 and inhibits its binding to PD-L1 and PD-L2, preventing PD-1-mediated immune escape of cancer cells [18]. Here, CD274 is linked to cancer.